Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF-REVERT phase 2 trial of CDR132L after myocardial infarction with reduced LVEF
NL-OMON53818Phase 2Recruiting
- Sponsor
- IQVIA Biotech
- Start
- Jul 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of CDR132L in heart failure with reduced ejection fraction (HFrEF) and left ventricular systolic dysfunction (LVSD) (3 arms), sponsored by IQVIA Biotech. Primary endpoint: Primary efficacy endpoint. Started Jul 2022; status: recruiting.
02
Drugs
CDR132L
03
Conditions
heart failure with reduced ejection fraction (HFrEF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on NL-OMON53818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53818.